Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma

doi:10.2174/0929867327666201013162144
摘要

肝细胞癌（HCC）是全球最常见的恶性肿瘤之一，每年新增病例和死亡人数近百万。由于发病机制复杂、早期症状隐匿、进展迅速、预后差，HCC的发病率和死亡率逐年增加。随着现代医学的进步，HCC的治疗不再局限于传统方法。近年来出现了靶向治疗和免疫治疗来治疗晚期和转移性 HCC。由于索拉非尼是第一个针对血管生成的分子靶向药物，因此针对 HCC 的靶向药物不断涌现。此外，免疫疗法在临床试验中起着至关重要的作用。尤其是在癌症治疗领域越来越受到关注的免疫检查点抑制剂的应用，是一条可能的研究路径。有趣的是，这两种疗法通常在 HCC 的某些阶段相互补充，为晚期 HCC 患者带来了新的希望。本文就近年来HCC靶向治疗和免疫治疗的研究进展进行综述，为进一步开发HCC药物提供参考。
关键词: 肝细胞癌、蛋白激酶、药物设计、分子靶向、免疫检查点抑制剂、联合治疗。
« Previous Next »
[1] 
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.,  2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID:  30207593] 
[2] 
Chen, W.; Zheng, R.; Baade, P.D.; Zhang, S.; Zeng, H.; Bray, F.; Jemal, A.; Yu, X.Q.; He, J. Cancer statistics in China, 2015. CA Cancer J. Clin.,  2016, 66(2), 115-132.
[http://dx.doi.org/10.3322/caac.21338] [PMID:  26808342] 
[3] 
Zhang, Y.; Ren, J-S.; Shi, J-F.; Li, N.; Wang, Y-T.; Qu, C.; Zhang, Y.; Dai, M. International trends in primary liver cancer incidence from 1973 to 2007. BMC Cancer,  2015, 15(1), 94.
[http://dx.doi.org/10.1186/s12885-015-1113-4] [PMID:  25879744] 
[4] 
Bruix, J.; Sherman, M. American Association for the study of liver diseases. Management of hepatocellular carcinoma: an update. Hepatology,  2011, 53(3), 1020-1022.
[http://dx.doi.org/10.1002/hep.24199] [PMID:  21374666] 
[5] 
Fu, J.; Wang, H. Precision diagnosis and treatment of liver cancer in China. Cancer Lett.,  2018, 412, 283-288.
[http://dx.doi.org/10.1016/j.canlet.2017.10.008] [PMID:  29050983] 
[6] 
Are, C.; Meyer, B.; Stack, A.; Ahmad, H.; Smith, L.; Qian, B.; Song, T.; Chowdhury, S. Global trends in the burden of liver cancer. J. Surg. Oncol.,  2017, 115(5), 591-602.
[http://dx.doi.org/10.1002/jso.24518] [PMID:  28345140] 
[7] 
Liu, Z.; Lin, Y.; Zhang, J.; Zhang, Y.; Li, Y.; Liu, Z.; Li, Q.; Luo, M.; Liang, R.; Ye, J. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J. Exp. Clin. Cancer Res.,  2019, 38(1), 447-460.
[http://dx.doi.org/10.1186/s13046-019-1412-8] [PMID:  31684985] 
[8] 
Hato, T.; Goyal, L.; Greten, T.F.; Duda, D.G.; Zhu, A.X. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology,  2014, 60(5), 1776-1782.
[http://dx.doi.org/10.1002/hep.27246] [PMID:  24912948] 
[9] 
Kudo, M. Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials. Oncology,  2017, 92(1), 50-62.
[http://dx.doi.org/10.1159/000451016] [PMID:  28147363] 
[10] 
Iñarrairaegui, M.; Melero, I.; Sangro, B. Immunotherapy of hepatocellular carcinoma: facts and hopes. Clin. Cancer Res.,  2018, 24(7), 1518-1524.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-0289] [PMID:  29138342] 
[11] 
Kudo, M. Combination cancer immunotherapy in hepatocellular carcinoma. Liver Cancer,  2018, 7(1), 20-27.
[http://dx.doi.org/10.1159/000486487] [PMID:  29662830] 
[12] 
Rimassa, L.; Assenat, E.; Peck-Radosavljevic, M.; Pracht, M.; Zagonel, V.; Mathurin, P.; Rota Caremoli, E.; Porta, C.; Daniele, B.; Bolondi, L.; Mazzaferro, V.; Harris, W.; Damjanov, N.; Pastorelli, D.; Reig, M.; Knox, J.; Negri, F.; Trojan, J.; López López, C.; Personeni, N.; Decaens, T.; Dupuy, M.; Sieghart, W.; Abbadessa, G.; Schwartz, B.; Lamar, M.; Goldberg, T.; Shuster, D.; Santoro, A.; Bruix, J. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol.,  2018, 19(5), 682-693.
[http://dx.doi.org/10.1016/S1470-2045(18)30146-3] [PMID:  29625879] 
[13] 
Kobayashi, S.; Ueshima, K.; Moriguchi, M.; Takayama, T.; Izumi, N.; Yoshiji, H.; Hino, K.; Oikawa, T.; Chiba, T.; Motomura, K.; Kato, J.; Yasuchika, K.; Ido, A.; Kinoshita, J.; Sato, T.; Ikeda, M.; Okusaka, T.; Kudo, M.; Tamura, K.; Furuse, J. JET-HCC: a phase 3 randomized, double-blind, placebo-controlled study of tivantinib as a second-line therapy in patients with c-Met high hepatocellular carcinoma. Ann. Oncol.,  2017, 28(Suppl. 5), v210.
[http://dx.doi.org/10.1093/annonc/mdx369.003] 
[14] 
Abou-Alfa, G.K.; Meyer, T.; Cheng, A-L.; El-Khoueiry, A.B.; Rimassa, L.; Ryoo, B-Y.; Cicin, I.; Merle, P.; Chen, Y.; Park, J-W.; Blanc, J.F.; Bolondi, L.; Klümpen, H.J.; Chan, S.L.; Zagonel, V.; Pressiani, T.; Ryu, M.H.; Venook, A.P.; Hessel, C.; Borgman-Hagey, A.E.; Schwab, G.; Kelley, R.K. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med.,  2018, 379(1), 54-63.
[http://dx.doi.org/10.1056/NEJMoa1717002] [PMID:  29972759] 
[15] 
Kelley, R.K.; Verslype, C.; Cohn, A.L.; Yang, T-S.; Su, W-C.; Burris, H.; Braiteh, F.; Vogelzang, N.; Spira, A.; Foster, P.; Lee, Y.; Van Cutsem, E. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann. Oncol.,  2017, 28(3), 528-534.
[http://dx.doi.org/10.1093/annonc/mdw651] [PMID:  28426123] 
[16] 
Yau, T.C.; Sukeepaisarnjaroen, W.; Chao, Y.; Yen, C.-J.; Lausoontornsiri, W.; Chen, P.-J.; Sanpajit, T.; Lencioni, R.; Camp, A.C.; Cox, D.S.; Kallender, H.; Ottesen, L.H.; Poon, R.T.-P. phase I/II study of foretinib, an oral multikinaseinhibitor targeting MET, RON, AXL, TIE-2 and VEGFR inadvanced hepatocellular carcinoma (HCC). J. Clin. Oncol,  2012, 30(15_suppl.), 4108.
[http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4108] 
[17] 
Bang, Y-J.; Su, W-C.; Nam, D-H.; Lim, W-T.; Bauer, T.M.; Brana, I.; Poon, R.T-P.; Hong, D.S.; Lin, C-C.; Peng, B.; Zhang, Y.; Zhao, S.; Kumar, A.; Akimov, M.; Ma, B. Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors. J. Clin. Oncol.,  2014, 32(15), 2520.
[http://dx.doi.org/10.1200/jco.2014.32.15_suppl.2520] 
[18] 
Qin, S.; Chan, S.L.; Sukeepaisarnjaroen, W.; Han, G.; Choo, S.P.; Sriuranpong, V.; Pan, H.; Yau, T.; Guo, Y.; Chen, M.; Ren, Z.; Xu, J.; Yen, C.J.; Lin, Z.Z.; Manenti, L.; Gu, Y.; Sun, Y.; Tiedt, R.; Hao, L.; Song, W.; Tanwandee, T. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. Ther. Adv. Med. Oncol.,  2019, 11, 1758835919889001.
[http://dx.doi.org/10.1177/1758835919889001] [PMID:  31853265] 
[19] 
O’Neil, B.H.; Bendell, J.C.; Modiano, M.R.; Machiels, J-P.H.; Versola, M.J.; Hodge, J.P.; Sawarna, K.; Tse, N. Phase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): phase I results. J. Clin. Oncol.,  2013, 31, 294.
[http://dx.doi.org/10.1200/jco.2013.31.4_suppl.294] 
[20] 
Decaens, T.; Barone, C.; Assenat, E.; Wermke, M.; Fasolo, A.; Merle, P.; Blanc, J.F.; Grando, V.; Bruns, R.; Straub, J.; Zhao, C.; Faivre, S. Phase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenibtreated advanced hepatocellular carcinoma (HCC). Ann. Oncol,  2018, 29(8), viii235.
[http://dx.doi.org/10.1093/annonc/mdy282.081] 
[21] 
Ryoo, B.-Y.; Ren, Z.; Kim, T.-Y.; Pan, H.; Rau, K.-M.; Choi, H.J.; Park, J.-W.; Kim, J.H.; Yen, C.-J.; Kim, B.-H.; Zhou, D.; Straub, J.; Zhao, C.; Qin, S. Phase II trial of tepotinib vs. sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC). Ann. Oncol,  2018, 29(8), viii207.
[http://dx.doi.org/10.1093/annonc/mdy282.005] 
[22] 
Harding, J.J.; Bendell, J.C.; Fuchs, C.S.; Wang, X.; Wacheck, V.; Zhu, A.X. Emibetuzumab plus ramucirumab: simultaneous targeting of MET and VEGFR-2 in patients with advanced hepatocellular cancer in a phase 1b/2 study. J. Clin. Oncol.,  2016, 34(4), 300.
[http://dx.doi.org/10.1200/jco.2016.34.4_suppl.300] 
[23] 
Cid, R.A.P.; Esquerdo, G.; Puertolas, T.; Calderero, V.; Gil, I.; Lao, J.; Millastre, E.; Alvarez-Alejandro, M.; Madani, J.; Anton, A. Bevacizumab (BVZ) as second-line treatment after sorafenib (SFB) progression in patients (pts) with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol.,  2010, 28(15), e14619.
[http://dx.doi.org/10.1200/jco.2010.28.15_suppl.e14619] 
[24] 
Chuah, B.; Lim, R.; Boyer, M.; Ong, A-B.; Wong, S-W.; Kong, H-L.; Millward, M.; Clarke, S.; Goh, B-C. Multi-centre phase II trial of thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol.,  2007, 46(2), 234-238.
[http://dx.doi.org/10.1080/02841860600702076] [PMID:  17453375] 
[25] 
Chen, Y-Y.; Yen, H-H.; Chou, K-C.; Wu, S-S. Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis. World J. Gastroenterol.,  2012, 18(5), 466-471.
[http://dx.doi.org/10.3748/wjg.v18.i5.466] [PMID:  22346253] 
[26] 
Bruix, J.; Qin, S.; Merle, P.; Granito, A.; Huang, Y-H.; Bodoky, G.; Pracht, M.; Yokosuka, O.; Rosmorduc, O.; Breder, V.; Gerolami, R.; Masi, G.; Ross, P.J.; Song, T.; Bronowicki, J.P.; Ollivier-Hourmand, I.; Kudo, M.; Cheng, A.L.; Llovet, J.M.; Finn, R.S.; LeBerre, M.A.; Baumhauer, A.; Meinhardt, G.; Han, G. RESORCE InvestigatorsRegorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet,  2017, 389(10064), 56-66.
[http://dx.doi.org/10.1016/S0140-6736(16)32453-9] [PMID:  27932229] 
[27] 
Finn, R.S.; Merle, P.; Granito, A.; Huang, Y-H.; Bodoky, G.; Pracht, M.; Yokosuka, O.; Rosmorduc, O.; Gerolami, R.; Caparello, C.; Cabrera, R.; Chang, C.; Sun, W.; LeBerre, M.A.; Baumhauer, A.; Meinhardt, G.; Bruix, J. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial. J. Hepatol.,  2018, 69(2), 353-358.
[http://dx.doi.org/10.1016/j.jhep.2018.04.010] [PMID:  29704513] 
[28] 
Kudo, M.; Finn, R.S.; Qin, S.; Han, K-H.; Ikeda, K.; Piscaglia, F.; Baron, A.; Park, J-W.; Han, G.; Jassem, J.; Blanc, J.F.; Vogel, A.; Komov, D.; Evans, T.R.J.; Lopez, C.; Dutcus, C.; Guo, M.; Saito, K.; Kraljevic, S.; Tamai, T.; Ren, M.; Cheng, A.L. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet,  2018, 391(10126), 1163-1173.
[http://dx.doi.org/10.1016/S0140-6736(18)30207-1] [PMID:  29433850] 
[29] 
Cainap, C.; Qin, S.; Huang, W-T.; Chung, I.J.; Pan, H.; Cheng, Y.; Kudo, M.; Kang, Y-K.; Chen, P-J.; Toh, H-C.; Gorbunova, V.; Eskens, F.A.; Qian, J.; McKee, M.D.; Ricker, J.L.; Carlson, D.M.; El-Nowiem, S. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J. Clin. Oncol.,  2015, 33(2), 172-179.
[http://dx.doi.org/10.1200/JCO.2013.54.3298] [PMID:  25488963] 
[30] 
Zhu, A.X.; Ryoo, B-Y.; Yen, C-J.; Kudo, M.; Poon, R.T-P.; Pastorelli, D.; Blanc, J-F.; Chung, H.C.; Baron, A.D.; Pfiffer, T.E.F.; Okusaka, T.; Kubackova, K.; Trojan, J.; Sastre, J.; Chau, I.; Chang, S-C.; Abada, P.; Yang, L.; Hsu, Y.; Park, J.O. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): analysis of patients with elevated α-fetoprotein (AFP) from the randomized phase III REACH study. J. Clin. Oncol.,  2015, 33(3), 232.
[http://dx.doi.org/10.1200/jco.2015.33.3_suppl.232] 
[31] 
Zhu, A.X.; Kang, Y-K.; Yen, C-J.; Finn, R.S.; Galle, P.R.; Llovet, J.M.; Assenat, E.; Brandi, G.; Lim, H.Y.; Pracht, M.; Rau, K-M.; Merle, P.; Motomura, K.; Ohno, I.; Daniele, B.; Shin, D.; Gerken, G.; Abada, P.; Hsu, Y.; Kudo, M. REACH-2: a randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. J. Clin. Oncol.,  2018, 36(15), 4003.
[http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.4003] 
[32] 
Yau, T.; Chen, P-J.; Chan, P.; Curtis, C.M.; Murphy, P.S.; Suttle, A.B.; Gauvin, J.; Hodge, J.P.; Dar, M.M.; Poon, R.T. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics and pharmacodynamics. Clin. Cancer Res.,  2011, 17(21), 6914-6923.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-0793] [PMID:  21831954] 
[33] 
Qin, S. Apatinib in Chinese patients with advanced hepatocellular carcinoma: a phase II randomized, open-label trial. J. Clin. Oncol.,  2014, 32(15), 4019.
[http://dx.doi.org/10.1200/jco.2014.32.15_suppl.4019] 
[34] 
McNamara, M.G.; Le, L.W.; Horgan, A.M.; Aspinall, A.; Burak, K.W.; Dhani, N.; Chen, E.; Sinaei, M.; Lo, G.; Kim, T.K.; Rogalla, P.; Bathe, O.F.; Knox, J.J. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. Cancer,  2015, 121(10), 1620-1627.
[http://dx.doi.org/10.1002/cncr.29227] [PMID:  25565269] 
[35] 
Kang, Y-K.; Yau, T.; Park, J-W.; Lim, H.Y.; Lee, T-Y.; Obi, S.; Chan, S.L.; Qin, S.; Kim, R.D.; Casey, M.; Chen, C.; Bhattacharyya, H.; Williams, J.A.; Valota, O.; Chakrabarti, D.; Kudo, M. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann. Oncol.,  2015, 26(12), 2457-2463.
[http://dx.doi.org/10.1093/annonc/mdv388] [PMID:  26386123] 
[36] 
Zhu, A.X.; Stuart, K.; Blaszkowsky, L.S.; Muzikansky, A.; Reitberg, D.P.; Clark, J.W.; Enzinger, P.C.; Bhargava, P.; Meyerhardt, J.A.; Horgan, K.; Fuchs, C.S.; Ryan, D.P. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer,  2007, 110(3), 581-589.
[http://dx.doi.org/10.1002/cncr.22829] [PMID:  17583545] 
[37] 
O’Dwyer, P.J.; Giantonio, B.J.; Levy, D.E.; Kauh, J.S.; Fitzgerald, D.B.; Benson, A.B. III. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the eastern cooperative oncology group’s study E1203. J. Clin. Oncol.,  2006, 24(18), 4143.
[http://dx.doi.org/10.1200/jco.2006.24.18_suppl.4143] 
[38] 
Zhang, J.; Zong, Y.; Xu, G.Z.; Xing, K. Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials. Saudi Med. J.,  2016, 37(11), 1184-1190.
[http://dx.doi.org/10.15537/smj.2016.11.16267] [PMID:  27761555] 
[39] 
Bekaii-Saab, T.; Markowitz, J.; Prescott, N.; Sadee, W.; Heerema, N.; Wei, L.; Dai, Z.; Papp, A.; Campbell, A.; Culler, K.; Balint, C.; O’Neil, B.; Lee, R.M.; Zalupski, M.; Dancey, J.; Chen, H.; Grever, M.; Eng, C.; Villalona-Calero, M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin. Cancer Res.,  2009, 15(18), 5895-5901.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-0465] [PMID:  19737952] 
[40] 
Geissler, E.K.; Schnitzbauer, A.A.; Zülke, C.; Lamby, P.E.; Proneth, A.; Duvoux, C.; Burra, P.; Jauch, K-W.; Rentsch, M.; Ganten, T.M.; Schmidt, J.; Settmacher, U.; Heise, M.; Rossi, G.; Cillo, U.; Kneteman, N.; Adam, R.; van Hoek, B.; Bachellier, P.; Wolf, P.; Rostaing, L.; Bechstein, W.O.; Rizell, M.; Powell, J.; Hidalgo, E.; Gugenheim, J.; Wolters, H.; Brockmann, J.; Roy, A.; Mutzbauer, I.; Schlitt, A.; Beckebaum, S.; Graeb, C.; Nadalin, S.; Valente, U.; Turrión, V.S.; Jamieson, N.; Scholz, T.; Colledan, M.; Fändrich, F.; Becker, T.; Söderdahl, G.; Chazouillères, O.; Mäkisalo, H.; Pageaux, G.P.; Steininger, R.; Soliman, T.; de Jong, K.P.; Pirenne, J.; Margreiter, R.; Pratschke, J.; Pinna, A.D.; Hauss, J.; Schreiber, S.; Strasser, S.; Klempnauer, J.; Troisi, R.I.; Bhoori, S.; Lerut, J.; Bilbao, I.; Klein, C.G.; Königsrainer, A.; Mirza, D.F.; Otto, G.; Mazzaferro, V.; Neuhaus, P.; Schlitt, H.J. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation,  2016, 100(1), 116-125.
[http://dx.doi.org/10.1097/TP.0000000000000965] [PMID:  26555945] 
[41] 
Zhang, Z-H.; Li, L.X.; Li, P.; Lv, S-C.; Pan, B.; He, Q. Sirolimus in liver transplant recipients with hepatocellular carcinoma: an updated meta-analysis. J. Invest. Surg.,  2019, 32(7), 632-641.
[http://dx.doi.org/10.1080/08941939.2018.1447053] [PMID:  29557691] 
[42] 
Yeo, W.; Chan, S.L.; Mo, F.K.; Chu, C.M.; Hui, J.W.; Tong, J.H.; Chan, A.W.; Koh, J.; Hui, E.P.; Loong, H.; Lee, K.; Li, L.; Ma, B.; To, K.F.; Yu, S.C. Phase I/II study of temsirolimus for patients with unresectable hepatocellular carcinoma (HCC)-a correlative study to explore potential biomarkers for response. BMC Cancer,  2015, 15(1), 395.
[http://dx.doi.org/10.1186/s12885-015-1334-6] [PMID:  25962426] 
[43] 
Zhu, A.X.; Kudo, M.; Assenat, E.; Cattan, S.; Kang, Y-K.; Lim, H.Y.; Poon, R.T.P.; Blanc, J-F.; Vogel, A.; Chen, C-L.; Dorval, E.; Peck-Radosavljevic, M.; Santoro, A.; Daniele, B.; Furuse, J.; Jappe, A.; Perraud, K.; Anak, O.; Sellami, D.B.; Chen, L-T. EVOLVE-1: phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. J. Clin. Oncol.,  2014, 32(3), 172.
[http://dx.doi.org/10.1200/jco.2014.32.3_suppl.172] 
[44] 
Koeberle, D.; Dufour, J-F.; Demeter, G.; Li, Q.; Ribi, K.; Samaras, P.; Saletti, P.; Roth, A.D.; Horber, D.; Buehlmann, M.; Wagner, A.D.; Montemurro, M.; Lakatos, G.; Feilchenfeldt, J.; Peck-Radosavljevic, M.; Rauch, D.; Tschanz, B.; Bodoky, G. Swiss Group for Clinical Cancer Research (SAKK). Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann. Oncol.,  2016, 27(5), 856-861.
[http://dx.doi.org/10.1093/annonc/mdw054] [PMID:  26884590] 
[45] 
Treiber, G.; Wex, T.; Schneider, G.; Roecken, C.; Dufour, J-F.; Geisel, J.; Hardikar, S.; Group, G.M.B.S. Treatment of advanced or metastatic hepatocellular cancer (HCC): final clinical results of a single-arm phase II study of bevacizumab and everolimus. J. Clin. Oncol.,  2012, 30(15), 4107.
[http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4107] 
[46] 
Salkeni, M.A.; Rixe, O.; Karim, N.A.; Ogara, S.; Feiler, M.; Moorthy, G.; Mercer, C.A.; Thomas, H.; Desai, P.B.; Fathallah, H.; Kozma, S.; Thomas, G.; Morris, J.C. BEZ235 in combination with everolimus for advanced solid malignancies: preliminary results of a phase Ib dose-escalation study J. Clin. Oncol,  2013, 31(15_suppl), , e13518..
[http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e13518] 
[47] 
Jackson, R.; Psarelli, E-E.; Berhane, S.; Khan, H.; Johnson, P. Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized phase III trials. J. Clin. Oncol.,  2017, 35(6), 622-628.
[http://dx.doi.org/10.1200/JCO.2016.69.5197] [PMID:  28045619] 
[48] 
Liu, J.; Li, X.; Zhang, H.; Chen, G.; Chen, H.; Hu, Y.; Niu, J.; Ding, Y. Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: report from a phase 1b trial. Pharmazie,  2019, 74(11), 688-693.
[http://dx.doi.org/10.1691/ph.2019.9626]] [PMID:  31739839] 
[49] 
Bi, F.; Qiu, M.; Chai, X.; Niu, J.; Ding, Y.; Bai, Y.; Wu, L.; Shentu, J.; Hao, P.; Chen, J.; Li, Q. A multicenter phase II study of donafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol,  2019, 35((15_suppl), e15682.
[http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.e15682] 
[50] 
Wang, E.; Kim, D.W.; Mahipal, A.; Chen, D-T.; Cao, B.; Masawi, F.; Kim, R.D. Phase I study of tramatinib combined with sorafenib in patients (pts) with advanced hepatocellular cancer (HCC). J. Clin. Oncol.,  2019, 37(4), 431.
[http://dx.doi.org/10.1691/10.1200/JCO.2019.37.4_suppl.431] 
[51] 
O’Neil, B.H.; Goff, L.W.; Kauh, J.S.W.; Strosberg, J.R.; Bekaii-Saab, T.S.; Lee, R.M.; Kazi, A.; Moore, D.T.; Learoyd, M.; Lush, R.M.; Sebti, S.M.; Sullivan, D.M. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol.,  2011, 29(17), 2350-2356.
[http://dx.doi.org/10.1200/JCO.2010.33.9432] [PMID:  21519015] 
[52] 
Lim, H.Y.; Heo, J.; Choi, H.J.; Lin, C-Y.; Yoon, J-H.; Hsu, C.; Rau, K-M.; Poon, R.T.P.; Yeo, W.; Park, J-W.; Tay, M.H.; Hsieh, W-S.; Kappeler, C.; Rajagopalan, P.; Krissel, H.; Jeffers, M.; Yen, C-J.; Tak, W.Y. A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Clin. Cancer Res.,  2014, 20(23), 5976-5985.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-3445] [PMID:  25294897] 
[53] 
Lim, H.Y.; Merle, P.; Weiss, K.H.; Yau, T.; Ross, P.; Mazzaferro, V.; Blanc, J-F.; Ma, Y.T.; Yen, C.J.; Kocsis, J.; Choo, S.P.; Sukeepaisarnjaroen, W.; Gérolami, R.; Dufour, J-F.; Gane, E.J.; Ryoo, B-Y.; Peck-Radosavljevic, M.; Dao, T.; Yeo, W.; Lamlertthon, W.; Thongsawat, S.; Teufel, M.; Roth, K.; Reis, D.; Childs, B.H.; Krissel, H.; Llovet, J.M. Phase II studies with refametinib or refametinib plus sorafenib in patients with ras-mutated hepatocellular carcinoma. Clin. Cancer Res.,  2018, 24(19), 4650-4661.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-3588] [PMID:  29950351] 
[54] 
Yamazaki, K.; Doi, T.; Ikeda, M.; Okusaka, T.; Schueler, A.; Watanabe, M.; Ohtsu, A. Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma. Cancer Chemother. Pharmacol.,  2019, 84(5), 1027-1037.
[http://dx.doi.org/10.1007/s00280-019-03924-0] [PMID:  31482223] 
[55] 
El-Khoueiry, A.B.; Sangro, B.; Yau, T.; Crocenzi, T.S.; Kudo, M.; Hsu, C.; Kim, T-Y.; Choo, S-P.; Trojan, J.; Welling, T.H. III.; Meyer, T.; Kang, Y.K.; Yeo, W.; Chopra, A.; Anderson, J.; Cruz, D.C.; Lang, L.; Neely, J.; Tang, H.; Dastani, H.B.; Melero, I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet,  2017, 389(10088), 2492-2502.
[http://dx.doi.org/10.1016/S0140-6736(17)31046-2] [PMID:  28434648] 
[56] 
Zhu, A.X.; Finn, R.S.; Edeline, J.; Cattan, S.; Ogasawara, S.; Palmer, D.; Verslype, C.; Zagonel, V.; Fartoux, L.; Vogel, A.; Sarker, D.; Verset, G.; Chan, S.L.; Knox, J.; Daniele, B.; Webber, A.L.; Ebbinghaus, S.W.; Ma, J.; Siegel, A.B.; Cheng, A.L.; Kudo, M. KEYNOTE-224 investigators Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol.,  2018, 19(7), 940-952.
[http://dx.doi.org/10.1016/S1470-2045(18)30351-6] [PMID:  29875066] 
[57] 
Qin, S.; Finn, R.S.; Kudo, M.; Meyer, T.; Vogel, A.; Ducreux, M.; Macarulla, T.M.; Tomasello, G.; Boisserie, F.; Hou, J.; Li, X.; Song, J.; Zhu, A.X. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncol.,  2019, 15(16), 1811-1822.
[http://dx.doi.org/10.2217/fon-2019-0097] [PMID:  30969136] 
[58] 
Deva, S.; Lee, J.S.; Lin, C.C.; Yen, C.J.; Millward, M.; Chao, Y.; Keam, B.; Jameson, M.; Hou, M.M.; Kang, Y.K.; Markman, B.; Lu, C.H.; Rau, K.M.; Lee, K.H.; Horvath, L.; Friedlander, M.; Hill, A.; Wu, J.; Hou, J.; Desai, J. A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors. Ann. Oncol.,  2018, 29(10), 24-38.
[http://dx.doi.org/10.1093/annonc/mdy487.042] 
[59] 
Qin, S.K.; Ren, Z.G.; Meng, Z.Q.; Chen, Z.D.; Chai, X.L.; Xiong, J.P.; Bai, Y.X.; Yang, L.; Zhu, H.; Fang, W.J.; Lin, X.Y.; Chen, X.M.; Li, E.X.; Xia, Y.; Zou, J.J. A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment. Ann. Oncol.,  2018, 29(8), 719-720.
[http://dx.doi.org/10.1093/annonc/mdy424.029] 
[60] 
Ando, Y.; Doi, T.; Mitsuma, A.; Mizutani, T.; Toyoda, M.; Imamura, Y.; Kiyota, N.; Naito, Y.; Matsubara, N.; Ishihara, K.; Tajima, T.; Tokushige, K.; Cameron, S.; Minami, H. Phase I study of spartalizumab (PDR001), an anti-PD1 mAb, in Japanese patients with advanced malignancies. Ann. Oncol.,  2018, 36(15), 6024.
[http://dx.doi.org/10.1093/annonc/mdy374.042] 
[61] 
Wainberg, Z.A.; Segal, N.H.; Jaeger, D.; Lee, K-H.; Marshall, J.; Antonia, S.J.; Butler, M.; Sanborn, R.E.; Nemunaitis, J.J.; Carlson, C.A. Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC). J. Clin. Oncol.,  2017, 35(15), 4071.
[http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.4071] 
[62] 
Shen, L.; Zhang, L.; Hu, X.; Pan, H.; Liu, T.; Bai, Y.; Chen, Y.C.; Huang, J.; Xu, T.; Hsu, W.; Shi, J. Atezolizumab monotherapy in Chinese patients with locally advanced or metastatic solid tumours. Ann. Oncol,  2018, 29(9_suppl.), ix49.
[http://dx.doi.org/10.1093/annonc/mdy432.006] 
[63] 
Lee, K-H. Phase II study of avelumab in patients with advanced hepatocellular carcinoma after prior sorafenib treatment (avelumab HCC), 2018. NCT No. NCT03389126. Available at: . https://clinicaltrials.gov/ct2/show/NCT03389-126
[64] 
Sangro, B.; Gomez-Martin, C.; de la Mata, M.; Iñarrairaegui, M.; Garralda, E.; Barrera, P.; Riezu-Boj, J.I.; Larrea, E.; Alfaro, C.; Sarobe, P.; Lasarte, J.J.; Pérez-Gracia, J.L.; Melero, I.; Prieto, J. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J. Hepatol.,  2013, 59(1), 81-88.
[http://dx.doi.org/10.1016/j.jhep.2013.02.022] [PMID:  23466307] 
[65] 
Yau, T.; Kang, Y-K.; Kim, T-Y.; El-Khoueiry, A.B.; Santoro, A.; Sangro, B.; Melero, I.; Kudo, M.; Hou, M-M.; Matilla, A.; Tovoli, F.; Knox, J.J.; He, A.R.; El-Rayes, B.F.; Acosta-Rivera, M.; Neely, J.; Shen, Y.; Baccan, C.; Cruz, C.M.D.; Hsu, C. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040. J. Clin. Oncol.,  2019, 37(15), 4012.
[http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.4012] 
[66] 
Kaseb, A.; Duda, D.G.; Cao, H.S.T.; Abugabal, Y.I.; Vence, L.M.; Rashid, A.; Pestana, R.C.; Blando, J.M.; Singh, S.; Vauthey, J.N.; Chun, Y.S.; Tzeng, C.W.D.; Sakamuri, D.; Wolff, R.A.; Yao, J.C.; Allison, J.; Sharma, P. Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC. Ann. Oncol.,  2019, 37(15), 4098.
[http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.4098] 
[67] 
Pishvaian, M.J.; Lee, M.S.; Ryoo, B-Y.; Stein, S.; Lee, K-H.; Verret, W.; Spahn, J.; Shao, H.; Liu, B.; Iizuka, K.; Hsu, C-H. Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Ann. Oncol.,  2018, 29(8), 718-719.
[http://dx.doi.org/10.1093/annonc/mdy424.028] 
[68] 
Cheng, A.L.; Qin, S.; Ikeda, M.; Galle, P.; Ducreux, M.; Zhu, A.; Kim, T.Y.; Kudo, M.; Breder, V.; Merle, P.; Kaseb, A.; Li, D.; Verret, W.; Xu, Z.; Hernandez, S.; Liu, J.; Huang, C.; Mulla, S.; Lim, H.Y.; Finn, R. IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs. sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann. Oncol.,  2019, 30(9), 186-187.
[http://dx.doi.org/10.1093/annonc/mdz446.002] 
[69] 
Ikeda, M.; Sung, M.W.; Kudo, M.; Kobayashi, M.; Baron, A.D.; Finn, R.S.; Kaneko, S.; Zhu, A.X.; Kubota, T.; Kraljevic, S.; Ishikawa, K.; Siegel, A.B.; Kumada, H.; Okusaka, T. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). J. Clin. Oncol.,  2018, 36(15), 4076.
[http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.4076] 
[70] 
Llovet, J.M.; Kudo, M.; Cheng, A-L.; Finn, R.S.; Galle, P.R.; Kaneko, S.; Meyer, T.; Qin, S.; Dutcus, C.E.; Chen, E.; Dubrovsky, L.; Zhu, A.X. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): phase 3 LEAP-002 study. J. Clin. Oncol.,  2019, 37(15), TPS4152.
[http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.TPS4152] 
[71] 
Kudo, M.; Motomura, K.; Wada, Y.; Inaba, Y.; Sakamoto, Y.; Kurosaki, M.; Umeyama, Y.; Kamei, Y.; Yoshimitsu, J.; Fujii, Y.; Aizawa, M.; Robbins, P.B.; Furuse, J. First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: results from a phase 1b trial (VEGF Liver 100). J. Clin. Oncol.,  2019, 37(15), 4072.
[http://dx.doi.org/10.1200/10.1200/JCO.2019.37.15_suppl.4072] 
[72] 
Xu, J.; Zhang, Y.; Jia, R.; Yue, C.; Chang, L.; Liu, R.; Zhang, G.; Zhao, C.; Zhang, Y.; Chen, C.; Wang, Y.; Yi, X.; Hu, Z.; Zou, J.; Wang, Q. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. Clin. Cancer Res.,  2019, 25(2), 515-523.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-2484] [PMID:  30348638] 
[73] 
Yau, T.; Zagonel, V.; Santoro, A.; Acosta-Rivera, M.; Choo, S.P.; Matilla, A.; He, A.R.; Gracián, A.C.; El-Khoueiry, A.B.; Sangro, B.; Eldawy, T.; Bruix, J.; Frassineti, G.; Vaccaro, G.M.; Tschaika, M.; Scheffold, C.; Shen, Y.; Neely, J.; Piscaglia, F. Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040. J. Clin. Oncol.,  2020, 38(4), 478.
[http://dx.doi.org/10.1200/JCO.2020.38.4_suppl.478] 
[74] 
Dhanasekaran, R.; Bandoh, S.; Roberts, L.R. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000 Res.,  2016, 5, 879-894.
[http://dx.doi.org/10.12688/f1000research.6946.1] [PMID:  27239288] 
[75] 
Ranieri, G.; Pantaleo, M.; Piccinno, M.; Roncetti, M.; Mutinati, M.; Marech, I.; Patruno, R.; Rizzo, A.; Sciorsci, R.L. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review. Crit. Rev. Oncol. Hematol.,  2013, 88(2), 293-308.
[http://dx.doi.org/10.1016/j.critrevonc.2013.05.009] [PMID:  23768779] 
[76] 
Wee, P.; Wang, Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel),  2017, 9(5), 52.
[http://dx.doi.org/10.3390/cancers9050052]] [PMID:  28513565] 
[77] 
Gavrin, L.K.; Saiah, E. Approaches to discover non-ATP site kinase inhibitors. MedChemComm,  2013, 4(1), 41-51.
[http://dx.doi.org/10.1039/C2MD20180A] 
[78] 
Garuti, L.; Roberti, M.; Bottegoni, G. Non-ATP competitive protein kinase inhibitors. Curr. Med. Chem.,  2010, 17(25), 2804-2821.
[http://dx.doi.org/10.2174/092986710791859333] [PMID:  20586715] 
[79] 
Backes, A.; Zech, B.; Felber, B.; Klebl, B.; Müller, G. Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition. Expert Opin. Drug Discov.,  2008, 3(12), 1409-1425.
[http://dx.doi.org/10.1517/17460440802579975] [PMID:  23506106] 
[80] 
Gotink, K.J.; Verheul, H.M.W. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis,  2010, 13(1), 1-14.
[http://dx.doi.org/10.1007/s10456-009-9160-6] [PMID:  20012482] 
[81] 
Backes, A.; Zech, B.; Felber, B.; Klebl, B.; Müller, G. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert Opin. Drug Discov.,  2008, 3(12), 1427-1449.
[http://dx.doi.org/10.1517/17460440802580106] [PMID:  23506107] 
[82] 
Gao, F.; Deng, G.; Liu, W.; Zhou, K.; Li, M. Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway. Oncol. Rep.,  2017, 37(2), 1203-1211.
[http://dx.doi.org/10.3892/or.2017.5347] [PMID:  28075467] 
[83] 
Hu, C.T.; Wu, J.R.; Cheng, C.C.; Wu, W.S. The therapeutic targeting of hgf/c-Met signaling in hepatocellular carcinoma: alternative approaches. Cancers (Basel),  2017, 9(6), 58-67.
[http://dx.doi.org/10.3390/cancers9060058] [PMID:  28587113] 
[84] 
Bouattour, M.; Raymond, E.; Qin, S.; Cheng, A.L.; Stammberger, U.; Locatelli, G.; Faivre, S. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology,  2018, 67(3), 1132-1149.
[http://dx.doi.org/10.1002/hep.29496] [PMID:  28862760] 
[85] 
Yang, X.; Zhang, X.F.; Lu, X.; Jia, H.L.; Liang, L.; Dong, Q.Z.; Ye, Q.H.; Qin, L.X. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology,  2014, 59(5), 1874-1885.
[http://dx.doi.org/10.1002/hep.26941] [PMID:  24259426] 
[86] 
Li, N.; Fu, H.; Tie, Y.; Hu, Z.; Kong, W.; Wu, Y.; Zheng, X. MiR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett.,  2009, 275(1), 44-53.
[http://dx.doi.org/10.1016/j.canlet.2008.09.035] [PMID:  19006648] 
[87] 
Tan, S.; Li, R.; Ding, K.; Lobie, P.E.; Zhu, T. MiR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the hgf/c-Met pathway. FEBS Lett.,  2011, 585(14), 2229-2234.
[http://dx.doi.org/10.1016/j.febslet.2011.05.042] [PMID:  21658389] 
[88] 
Ghosh, A.; Dasgupta, D.; Ghosh, A.; Roychoudhury, S.; Kumar, D.; Gorain, M.; Butti, R.; Datta, S.; Agarwal, S.; Gupta, S.; Krishna Dhali, G.; Chowdhury, A.; Schmittgen, T.D.; Kundu, G.C.; Banerjee, S. MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2. Cell Death Dis.,  2017, 8(3), e2706-e2717.
[http://dx.doi.org/10.1038/cddis.2017.123] [PMID:  28358369] 
[89] 
Yao, Y.; Dou, C.; Lu, Z.; Zheng, X.; Liu, Q. MACC1 suppresses cell apoptosis in hepatocellular carcinoma by targeting the HGF/c-MET/AKT pathway. Cell. Physiol. Biochem.,  2015, 35(3), 983-996.
[http://dx.doi.org/10.1159/000369754] [PMID:  25660117] 
[90] 
You, H.; Ding, W.; Dang, H.; Jiang, Y.; Rountree, C.B. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology,  2011, 54(3), 879-889.
[http://dx.doi.org/10.1002/hep.24450] [PMID:  21618573] 
[91] 
Lee, J.J.X.; Chan, J.J.; Choo, S.P. Clinical development of c-MET inhibition in hepatocellular carcinoma. Diseases,  2015, 3(4), 306-324.
[http://dx.doi.org/10.3390/diseases3040306] [PMID:  28943627] 
[92] 
Rosen, L.S.; Goldman, J.W.; Algazi, A.P.; Turner, P.K.; Moser, B.; Hu, T.; Wang, X.A.; Tuttle, J.; Wacheck, V.; Wooldridge, J.E.; Banck, M. A first-in-human phase I study of a bivalent MET antibody, emibetuzumab (LY2875358), as monotherapy and in combination with erlotinib in advanced cancer. Clin. Cancer Res.,  2017, 23(8), 1910-1919.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-1418] [PMID:  27803065] 
[93] 
Santoro, A.; Rimassa, L.; Borbath, I.; Daniele, B.; Salvagni, S.; Van Laethem, J.L.; Van Vlierberghe, H.; Trojan, J.; Kolligs, F.T.; Weiss, A.; Miles, S.; Gasbarrini, A.; Lencioni, M.; Cicalese, L.; Sherman, M.; Gridelli, C.; Buggisch, P.; Gerken, G.; Schmid, R.M.; Boni, C.; Personeni, N.; Hassoun, Z.; Abbadessa, G.; Schwartz, B.; Von Roemeling, R.; Lamar, M.E.; Chen, Y.; Porta, C. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol.,  2013, 14(1), 55-63.
[http://dx.doi.org/10.1016/S1470-2045(12)70490-4] [PMID:  23182627] 
[94] 
Pievsky, D.; Pyrsopoulos, N. Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date. J. Hepatocell. Carcinoma,  2016, 3, 69-76.
[http://dx.doi.org/10.2147/JHC.S106072] [PMID:  27896243] 
[95] 
Xiang, Q.; Zhen, Z.; Deng, D.Y.; Wang, J.; Chen, Y.; Li, J.; Zhang, Y.; Wang, F.; Chen, N.; Chen, H.; Chen, Y. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma. J. Exp. Clin. Cancer Res.,  2015, 34(1), 118.
[http://dx.doi.org/10.1186/s13046-015-0238-2] [PMID:  26458953] 
[96] 
Yakes, F.M.; Chen, J.; Tan, J.; Yamaguchi, K.; Shi, Y.; Yu, P.; Qian, F.; Chu, F.; Bentzien, F.; Cancilla, B.; Orf, J.; You, A.; Laird, A.D.; Engst, S.; Lee, L.; Lesch, J.; Chou, Y.C.; Joly, A.H. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther.,  2011, 10(12), 2298-2308.
[http://dx.doi.org/10.1158/1535-7163.MCT-11-0264] [PMID:  21926191] 
[97] 
Huynh, H.; Ong, R.; Soo, K.C. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis,  2012, 15(1), 59-70.
[http://dx.doi.org/10.1007/s10456-011-9243-z] [PMID:  22187171] 
[98] 
Liu, X.; Wang, Q.; Yang, G.; Marando, C.; Koblish, H.K.; Hall, L.M.; Fridman, J.S.; Behshad, E.; Wynn, R.; Li, Y.; Boer, J.; Diamond, S.; He, C.; Xu, M.; Zhuo, J.; Yao, W.; Newton, R.C.; Scherle, P.A. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin. Cancer Res.,  2011, 17(22), 7127-7138.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-1157] [PMID:  21918175] 
[99] 
Doi, T. Results of phase 1 studies of golvatinib (E7050), a c-Met and eph receptor-targeted multi-kinase inhibitor, administered orally BID to patients with advanced solid tumors. Ann. Oncol.,  2012, 23, 3079.
[http://dx.doi.org/10.1016/S0923-7534(20)31988-8] 
[100] 
Falchook, G.S.; Hong, D.S.; Amin, H.M.; Fu, S.; Piha-Paul, S.A.; Janku, F.; Granda, J.G.; Zheng, H.; Klevesath, M.B.; Köhler, K.; Bladt, F.; Johne, A.; Kurzrock, R. Results of the first-in-human phase I trial assessing MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors. J. Clin. Oncol.,  2014, 32, 2521.
[http://dx.doi.org/10.1200/jco.2014.32.15_suppl.2521] 
[101] 
Yan, M.; Wang, H.; Wang, Q.; Zhang, Z.; Zhang, C. Allosteric inhibition of c-Met kinase in sub-microsecond molecular dynamics simulations induced by its inhibitor, tivantinib. Phys. Chem. Chem. Phys.,  2016, 18(15), 10367-10374.
[http://dx.doi.org/10.1039/C5CP07001E] [PMID:  27029952] 
[102] 
Dorsch, D.; Schadt, O.; Stieber, F.; Meyring, M.; Grädler, U.; Bladt, F.; Friese-Hamim, M.; Knühl, C.; Pehl, U.; Blaukat, A. Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors. Bioorg. Med. Chem. Lett.,  2015, 25(7), 1597-1602.
[http://dx.doi.org/10.1016/j.bmcl.2015.02.002] [PMID:  25736998] 
[103] 
Zhao, S.; Zhang, Y.; Zhou, H.; Xi, S.; Zou, B.; Bao, G.; Wang, L.; Wang, J.; Zeng, T.; Gong, P.; Zhai, X. Synthesis and biological evaluation of 4-(2-fluorophenoxy)-3,3′-bipyridine derivatives as potential c-met inhibitors. Eur. J. Med. Chem.,  2016, 120, 37-50.
[http://dx.doi.org/10.1016/j.ejmech.2016.04.062] [PMID:  27187857] 
[104] 
Zhang, W.; Ai, J.; Shi, D.; Peng, X.; Ji, Y.; Liu, J.; Geng, M.; Li, Y. Discovery of novel type II c-Met inhibitors based on BMS-777607. Eur. J. Med. Chem.,  2014, 80, 254-266.
[http://dx.doi.org/10.1016/j.ejmech.2014.04.056] [PMID:  24792774] 
[105] 
Li, S.; Huang, Q.; Liu, Y.; Zhang, X.; Liu, S.; He, C.; Gong, P. Design, synthesis and antitumour activity of bisquinoline derivatives connected by 4-oxy-3-fluoroaniline moiety. Eur. J. Med. Chem.,  2013, 64(6), 62-73.
[http://dx.doi.org/10.1016/j.ejmech.2013.04.001] [PMID:  23644189] 
[106] 
Tang, Q.; Wang, L.; Tu, Y.; Zhu, W.; Luo, R.; Tu, Q.; Wang, P.; Wu, C.; Gong, P.; Zheng, P. Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors. Bioorg. Med. Chem. Lett.,  2016, 26(7), 1680-1684.
[http://dx.doi.org/10.1016/j.bmcl.2016.02.059] [PMID:  26923692] 
[107] 
Lien, V.T.; Pettersen, S.; Haugen, M.H.; Olberg, D.E.; Maelandsmo, G.M.; Klaveness, J. Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors. Arch. Pharm. (Weinheim),  2019, 352(9), e1900101.
[http://dx.doi.org/10.1002/ardp.201900101] [PMID:  31414521] 
[108] 
Inagaki, Y.; Qi, F.; Gao, J.; Qu, X.; Hasegawa, K.; Sugawara, Y.; Tang, W.; Kokudo, N. Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth. Biosci. Trends,  2011, 5(2), 52-56.
[http://dx.doi.org/10.5582/bst.2011.v5.2.52] [PMID:  21572247] 
[109] 
Wu, J-R.; Hu, C-T.; You, R-I.; Ma, P-L.; Pan, S-M.; Lee, M-C.; Wu, W-S. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways. PLoS One,  2015, 10(1), e0114495.
[http://dx.doi.org/10.1371/journal.pone.0114495] [PMID:  25607934] 
[110] 
Zhao, M.; Wang, Y.; Liu, Y.; Zhang, W.; Liu, Y.; Yang, X.; Cao, Y.; Wang, S. C7 peptide inhibits hepatocellular carcinoma metastasis by targeting the HGF/c-Met signaling pathway. Cancer Biol. Ther.,  2019, 20(12), 1430-1442.
[http://dx.doi.org/10.1080/15384047.2019.1647051] [PMID:  31441380] 
[111] 
Kraizer, Y.; Mawasi, N.; Seagal, J.; Paizi, M.; Assy, N.; Spira, G. Vascular endothelial growth factor and angiopoietin in liver regeneration. Biochem. Biophys. Res. Commun.,  2001, 287(1), 209-215.
[http://dx.doi.org/10.1006/bbrc.2001.5548] [PMID:  11549276] 
[112] 
Sitohy, B.; Nagy, J.A.; Dvorak, H.F. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res.,  2012, 72(8), 1909-1914.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-3406] [PMID:  22508695] 
[113] 
Zhang, L.; Wang, J-N.; Tang, J-M.; Kong, X.; Yang, J-Y.; Zheng, F.; Guo, L-Y.; Huang, Y-Z.; Zhang, L.; Tian, L.; Cao, S.F.; Tuo, C.H.; Guo, H.L.; Chen, S.Y. VEGF is essential for the growth and migration of human hepatocellular carcinoma cells. Mol. Biol. Rep.,  2012, 39(5), 5085-5093.
[http://dx.doi.org/10.1007/s11033-011-1304-2] [PMID:  22161247] 
[114] 
Finn, R.S.; Zhu, A.X. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev. Anticancer Ther.,  2009, 9(4), 503-509.
[http://dx.doi.org/10.1586/era.09.6] [PMID:  19374603] 
[115] 
Hsu, C.H.; Yang, T.S.; Hsu, C.; Toh, H.C.; Epstein, R.J.; Hsiao, L.T.; Chen, P.J.; Lin, Z.Z.; Chao, T.Y.; Cheng, A.L. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br. J. Cancer,  2010, 102(6), 981-986.
[http://dx.doi.org/10.1038/sj.bjc.6605580] [PMID:  20160718] 
[116] 
Thomas, M.B.; Morris, J.S.; Chadha, R.; Iwasaki, M.; Kaur, H.; Lin, E.; Kaseb, A.; Glover, K.; Davila, M.; Abbruzzese, J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol.,  2009, 27(6), 843-850.
[http://dx.doi.org/10.1200/JCO.2008.18.3301] [PMID:  19139433] 
[117] 
Gao, J.Z.; Du, J.L.; Wang, Y.L.; Li, J.; Wei, L.X.; Guo, M.Z. Synergistic effects of curcumin and bevacizumab on cell signaling pathways in hepatocellular carcinoma. Oncol. Lett.,  2015, 9(1), 295-299.
[http://dx.doi.org/10.3892/ol.2014.2694] [PMID:  25435978] 
[118] 
Peuckmann, V.; Fisch, M.; Bruera, E. Potential novel uses of thalidomide: focus on palliative care. Drugs,  2000, 60(2), 273-292.
[http://dx.doi.org/10.2165/00003495-200060020-00003] [PMID:  10983733] 
[119] 
Broyl, A.; Kuiper, R.; van Duin, M.; van der Holt, B.; el Jarari, L.; Bertsch, U.; Zweegman, S.; Buijs, A.; Hose, D.; Lokhorst, H.M.; Goldschmidt, H.; Sonneveld, P. Dutch-Belgian HOVON groupGerman GMMG Group. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood,  2013, 121(4), 624-627.
[http://dx.doi.org/10.1182/blood-2012-06-438101] [PMID:  23233657] 
[120] 
Cao, D-D.; Xu, H-L.; Liu, L.; Zheng, Y-F.; Gao, S-F.; Xu, X-M.; Ge, W. Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget,  2017, 8(27), 44976-44993.
[http://dx.doi.org/10.18632/oncotarget.16689] [PMID:  28402958] 
[121] 
Ang, S-F.; Tan, S-H.; Toh, H-C.; Poon, D.Y.H.; Ong, S.Y.K.; Foo, K-F.; Choo, S-P. Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. Am. J. Clin. Oncol.,  2012, 35(3), 222-227.
[http://dx.doi.org/10.1097/COC.0b013e31820dbf56] [PMID:  21378539] 
[122] 
Anderson, K.C. Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin. Hematol.,  2005, 42(4)(Suppl. 4), S3-S8.
[http://dx.doi.org/10.1053/j.seminhematol.2005.10.001] [PMID:  16344099] 
[123] 
Woo, K.; Stewart, S.G.; Kong, G.S.; Finch-Edmondson, M.L.; Dwyer, B.J.; Yeung, S.Y.; Abraham, L.J.; Kampmann, S.S.; Diepeveen, L.A.; Passman, A.M.; Elsegood, C.L.; Tirnitz-Parker, J.E.; Callus, B.A.; Olynyk, J.K.; Yeoh, G.C. Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib. Eur. J. Med. Chem.,  2016, 120, 275-283.
[http://dx.doi.org/10.1016/j.ejmech.2016.03.015] [PMID:  27208658] 
[124] 
Wilhelm, S.M.; Dumas, J.; Adnane, L.; Lynch, M.; Carter, C.A.; Schütz, G.; Thierauch, K.H.; Zopf, D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer,  2011, 129(1), 245-255.
[http://dx.doi.org/10.1002/ijc.25864] [PMID:  21170960] 
[125] 
Kudo, M. Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma. Liver Cancer,  2018, 7(1), 1-19.
[http://dx.doi.org/10.1159/000487148] [PMID:  29662829] 
[126] 
Gardini, A.C.; Puzzoni, M.; Montagnani, F.; Marisi, G.; Tamburini, E.; Cucchetti, A.; Solaini, L.; Foschi, F.G.; Conti, F.; Ercolani, G.; Cascinu, S.; Scartozzi, M. Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials. OncoTargets Ther.,  2019, 12, 2981-2988.
[http://dx.doi.org/10.2147/OTT.S192572] [PMID:  31118665] 
[127] 
Toh, H.C.; Chen, P-J.; Carr, B.I.; Knox, J.J.; Gill, S.; Ansell, P.; McKeegan, E.M.; Dowell, B.; Pedersen, M.; Qin, Q.; Qian, J.; Scappaticci, F.A.; Ricker, J.L.; Carlson, D.M.; Yong, W.P. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer,  2013, 119(2), 380-387.
[http://dx.doi.org/10.1002/cncr.27758] [PMID:  22833179] 
[128] 
Boudou-Rouquette, P.; Tlemsani, C.; Blanchet, B.; Huillard, O.; Jouinot, A.; Arrondeau, J.; Thomas-Schoemann, A.; Vidal, M.; Alexandre, J.; Goldwasser, F. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. Expert Opin. Drug Metab. Toxicol.,  2016, 12(12), 1433-1444.
[http://dx.doi.org/10.1080/17425255.2016.1225038] [PMID:  27556889] 
[129] 
Kong, Y.; Sun, L.; Hou, Z.; Zhang, Y.; Chen, P.; Cui, Y.; Zhu, X.; Song, T.; Li, Q.; Li, H.; Zhang, T.; Qin, L. Apatinib is effective for treatment of advanced hepatocellular carcinoma. Oncotarget,  2017, 8(62), 105596-105605.
[http://dx.doi.org/10.18632/oncotarget.22337] [PMID:  29285275] 
[130] 
Yu, W-C.; Zhang, K-Z.; Chen, S-G.; Liu, W-F. Efficacy and safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: a prospective observation study. Medicine (Baltimore),  2018, 97(3), e9704.
[http://dx.doi.org/10.1097/MD.0000000000009704] [PMID:  29505026] 
[131] 
Kou, P.; Zhang, Y.; Shao, W.; Zhu, H.; Zhang, J.; Wang, H.; Kong, L.; Yu, J. Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. Oncotarget,  2017, 8(12), 20510-20515.
[http://dx.doi.org/10.18632/oncotarget.14724] [PMID:  28103584] 
[132] 
Chan, S.L.; Yeo, W.; Mo, F.; Chan, A.W.H.; Koh, J.; Li, L.; Hui, E.P.; Chong, C.C.N.; Lai, P.B.S.; Mok, T.S.K.; Yu, S.C.H. A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. Cancer,  2017, 123(20), 3977-3985.
[http://dx.doi.org/10.1002/cncr.30825] [PMID:  28640364] 
[133] 
Johnson, P.J.; Qin, S.; Park, J-W.; Poon, R.T.P.; Raoul, J-L.; Philip, P.A.; Hsu, C-H.; Hu, T-H.; Heo, J.; Xu, J.; Lu, L.; Chao, Y.; Boucher, E.; Han, K-H.; Paik, S-W.; Robles-Aviña, J.; Kudo, M.; Yan, L.; Sobhonslidsuk, A.; Komov, D.; Decaens, T.; Tak, W-Y. Jeng. L-B.; Liu, D.; Ezzeddine, R.; Walters, I.; Cheng, A.-L. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J. Clin. Oncol.,  2013, 31(28), 3517-3524.
[http://dx.doi.org/10.1200/JCO.2012.48.4410] [PMID:  23980084] 
[134] 
Llovet, J.M.; Decaens, T.; Raoul, J-L.; Boucher, E.; Kudo, M.; Chang, C.; Kang, Y-K.; Assenat, E.; Lim, H-Y.; Boige, V.; Mathurin, P.; Fartoux, L.; Lin, D-Y.; Bruix, J.; Poon, R.T.; Sherman, M.; Blanc, J-F.; Finn, R.S.; Tak, W-Y.; Chao, Y.; Ezzeddine, R.; Liu, D.; Walters, I.; Park, J-W. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J. Clin. Oncol.,  2013, 31(28), 3509-3516.
[http://dx.doi.org/10.1200/JCO.2012.47.3009] [PMID:  23980090] 
[135] 
Cheng, A.; Kang, Y.; Lin, D.; Park, J.; Kudo, M.; Qin, S.; Omata, M.; Lowenthal, S.W.P.; Lanzalone, S.; Yang, L.; Lechuga, M.; Raymond, E. SUN1170 HCC study group. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J. Clin. Oncol,  2011, 29(15_Suppl.), 4000.
[http://dx.doi.org/10.1200/jco.2011.29.15_suppl.4000] 
[136] 
Eldehna, W.M.; Abou-Seri, S.M.; El Kerdawy, A.M.; Ayyad, R.R.; Hamdy, A.M.; Ghabbour, H.A.; Ali, M.M.; Abou El Ella, D.A. Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives. Eur. J. Med. Chem.,  2016, 113, 50-62.
[http://dx.doi.org/10.1016/j.ejmech.2016.02.029] [PMID:  26922228] 
[137] 
Chen, J.; Sheng, C.Q.; Zheng, C.H.; Li, Y.W.; Zhu, J. Study of properties of VEGFR2 active site and binding mode of VEGFR2 and its inhibitors. Acta Chimica Sinica-Chinese Edition,  2007, 65(6), 547-552.
[138] 
Hoi, P.M.; Li, S.; Vong, C.T.; Tseng, H.H.L.; Kwan, Y.W.; Lee, S.M. Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors. Methods,  2015, 71, 85-91.
[http://dx.doi.org/10.1016/j.ymeth.2014.09.004] [PMID:  25239735] 
[139] 
Zhong, H.; Bowen, J.P. Molecular design and clinical development of VEGFR kinase inhibitors. Curr. Top. Med. Chem.,  2007, 7(14), 1379-1393.
[http://dx.doi.org/10.2174/156802607781696855] [PMID:  17692027] 
[140] 
Shi, L.; Wu, T-T.; Wang, Z.; Xue, J-Y.; Xu, Y-G. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors. Eur. J. Med. Chem.,  2014, 84, 698-707.
[http://dx.doi.org/10.1016/j.ejmech.2014.07.071] [PMID:  25064347] 
[141] 
Yang, Y.; Shi, L.; Zhou, Y.; Li, H.Q.; Zhu, Z.W.; Zhu, H.L. Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors. Bioorg. Med. Chem. Lett.,  2010, 20(22), 6653-6656.
[http://dx.doi.org/10.1016/j.bmcl.2010.09.014] [PMID:  20943391] 
[142] 
Liu, L.; Qin, S.; Zheng, Y.; Han, L.; Zhang, M.; Luo, N.; Liu, Z.; Gu, N.; Gu, X.; Yin, X. Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. Cancer Biol. Ther.,  2017, 18(3), 166-176.
[http://dx.doi.org/10.1080/15384047.2017.1282019] [PMID:  28368741] 
[143] 
Ku, C-Y.; Wang, Y-R.; Lin, H-Y.; Lu, S-C.; Lin, J-Y. Corosolic acid inhibits hepatocellular carcinoma cell migration by targeting the vegfr2/src/fak pathway. PLoS One,  2015, 10(5), e0126725.
[http://dx.doi.org/10.1371/journal.pone.0126725] [PMID:  25978354] 
[144] 
Zhang, H-H.; Zhang, Y.; Cheng, Y-N.; Gong, F-L.; Cao, Z-Q.; Yu, L-G.; Guo, X-L. Metformin incombination with curcumin inhibits the growth, metastasis and angiogenesis of hepatocellular carcinoma in vitro and in vivo. Mol. Carcinog.,  2018, 57(1), 44-56.
[http://dx.doi.org/10.1002/mc.22718] [PMID:  28833603] 
[145] 
Jiang, H.; Wu, D.; Xu, D.; Yu, H.; Zhao, Z.; Ma, D.; Jin, J. Eupafolin exhibits potent anti-angiogenic and antitumor activity in hepatocellular carcinoma. Int. J. Biol. Sci.,  2017, 13(6), 701-711.
[http://dx.doi.org/10.7150/ijbs.17534] [PMID:  28655996] 
[146] 
Arteaga, C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin. Oncol.,  2003, 30(3)(Suppl. 7), 3-14.
[http://dx.doi.org/10.1016/S0093-7754(03)70010-4] [PMID:  12840796] 
[147] 
Mitsudomi, T.; Yatabe, Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J.,  2010, 277(2), 301-308.
[http://dx.doi.org/10.1111/j.1742-4658.2009.07448.x] [PMID:  19922469] 
[148] 
Seshacharyulu, P.; Ponnusamy, M.P.; Haridas, D.; Jain, M.; Ganti, A.K.; Batra, S.K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets,  2012, 16(1), 15-31.
[http://dx.doi.org/10.1517/14728222.2011.648617] [PMID:  22239438] 
[149] 
Geng, J.; Li, X.; Lang, X.; Qiao, C.; Hu, M.; Yang, J.; Feng, J.; Lv, M. Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma. Technol. Cancer Res. Treat.,  2014, 13(4), 377-385.
[http://dx.doi.org/10.7785/tcrt.2012.500389] [PMID:  24325131] 
[150] 
Chen, W.; Shen, X.; Xia, X.; Xu, G.; Ma, T.; Bai, X.; Liang, T. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma. Liver Int.,  2012, 32(1), 70-77.
[http://dx.doi.org/10.1111/j.1478-3231.2011.02631.x] [PMID:  22098470] 
[151] 
Xue, F.; Liu, Y.; Zhang, H.; Wen, Y.; Yan, L.; Tang, Q.; Xiao, E.; Zhang, D. Let-7a enhances the sensitivity of hepatocellular carcinoma cells to cetuximab by regulating STAT3 expression. OncoTargets Ther.,  2016, 9, 7253-7261.
[http://dx.doi.org/10.2147/OTT.S116127] [PMID:  27932893] 
[152] 
Huang, S.; He, R.; Rong, M.; Dang, Y.; Chen, G. Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells. Biomed Res. Int.,  2014, 2014384121.
[http://dx.doi.org/10.1155/2014/384121] [PMID:  24895573] 
[153] 
Xue, F.; Liang, Y.; Li, Z.; Liu, Y.; Zhang, H.; Wen, Y.; Yan, L.; Tang, Q.; Xiao, E.; Zhang, D. MicroRNA-9 enhances sensitivity to cetuximab in epithelial phenotype hepatocellular carcinoma cells through regulation of the eukaryotic translation initiation factor 5A-2. Oncol. Lett.,  2018, 15(1), 813-820.
[http://dx.doi.org/10.3892/ol.2017.7399]] [PMID:  29399149] 
[154] 
Xue, F.; Liu, Y.; Chu, H.; Wen, Y.; Yan, L.; Tang, Q.; Xiao, E.; Zhang, D.; Zhang, H. eIF5A2 is an alternative pathway for cell proliferation in cetuximab-treated epithelial hepatocellular carcinoma. Am. J. Transl. Res.,  2016, 8(11), 4670-4681.
[PMID:  27904670] 
[155] 
Cui, S.X.; Zhang, Y.S.; Chu, J.H.; Song, Z.Y.; Qu, X.J. Des-gamma-carboxy prothrombin (DCP) antagonizes the effects of gefitinib on human hepatocellular carcinoma cells. Cell. Physiol. Biochem.,  2015, 35(1), 201-212.
[http://dx.doi.org/10.1159/000369688] [PMID:  25591763] 
[156] 
Shao, J.; Xu, Z.; Peng, X.; Chen, M.; Zhu, Y.; Xu, L.; Zhu, H.; Yang, B.; Luo, P.; He, Q. Gefitinib synergizes with irinotecan to suppress hepatocellular carcinoma via antagonizing Rad51-mediated DNA-repair. PLoS One,  2016, 11(1), e0146968.
[http://dx.doi.org/10.1371/journal.pone.0146968] [PMID:  26752698] 
[157] 
Gu, H.R.; Park, S.C.; Choi, S.J.; Lee, J.C.; Kim, Y.C.; Han, C.J.; Kim, J.; Yang, K.Y.; Kim, Y.J.; Noh, G.Y.; No, S.H.; Jeong, J.H. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells. Clin. Mol. Hepatol.,  2015, 21(1), 49-59.
[http://dx.doi.org/10.3350/cmh.2015.21.1.49] [PMID:  25834802] 
[158] 
Tong, Y.; Wang, M.; Huang, H.; Zhang, J.; Huang, Y.; Chen, Y.; Pan, H. Inhibitory effects of genistein in combination with gefitinib on the hepatocellular carcinoma Hep3B cell line. Exp. Ther. Med.,  2019, 18(5), 3793-3800.
[http://dx.doi.org/10.3892/etm.2019.8027] [PMID:  31611933] 
[159] 
Philip, P.A.; Mahoney, M.R.; Allmer, C.; Thomas, J.; Pitot, H.C.; Kim, G.; Donehower, R.C.; Fitch, T.; Picus, J.; Erlichman, C. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol.,  2005, 23(27), 6657-6663.
[http://dx.doi.org/10.1200/JCO.2005.14.696] [PMID:  16170173] 
[160] 
Zhu, A.X.; Rosmorduc, O.; Evans, T.R.J.; Ross, P.J.; Santoro, A.; Carrilho, F.J.; Bruix, J.; Qin, S.; Thuluvath, P.J.; Llovet, J.M.; Leberre, M-A.; Jensen, M.; Meinhardt, G.; Kang, Y-K. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol.,  2015, 33(6), 559-566.
[http://dx.doi.org/10.1200/JCO.2013.53.7746] [PMID:  25547503] 
[161] 
Thomas, M.B.; Garrett-Mayer, E.; Anis, M.; Anderton, K.; Bentz, T.; Edwards, A.; Brisendine, A.; Weiss, G.; Siegel, A.B.; Bendell, J.; Baron, A.; Duddalwar, V.; El-Khoueiry, A. A randomized phase ii open-label multi-institution study of the combination of bevacizumab and erlotinib compared to sorafenib in the first-line treatment of patients with advanced hepatocellular carcinoma. Oncology,  2018, 94(6), 329-339.
[http://dx.doi.org/10.1159/000485384] [PMID:  29719302] 
[162] 
Yu, H-C.; Chen, H-J.; Chang, Y-L.; Liu, C-Y.; Shiau, C-W.; Cheng, A-L.; Chen, K-F. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochem. Pharmacol.,  2013, 85(3), 356-366.
[http://dx.doi.org/10.1016/j.bcp.2012.11.009] [PMID:  23178652] 
[163] 
Chen, Y-J.; Chi, C-W.; Su, W-C.; Huang, H-L. Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma. Oncotarget,  2014, 5(13), 4845-4854.
[http://dx.doi.org/10.18632/oncotarget.2045] [PMID:  24947784] 
[164] 
Yan, Y-Y.; Guo, Y.; Zhang, W.; Ma, C-G.; Zhang, Y-X.; Wang, C.; Wang, H-X. Celastrol enhanced the anticancer effect of lapatinib in human hepatocellular carcinoma cells in vitro. J. BUON,  2014, 19(2), 412-418.
[PMID:  24965400] 
[165] 
Yun, C-H.; Boggon, T.J.; Li, Y.; Woo, M.S.; Greulich, H.; Meyerson, M.; Eck, M.J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell,  2007, 11(3), 217-227.
[http://dx.doi.org/10.1016/j.ccr.2006.12.017] [PMID:  17349580] 
[166] 
Park, J.H.; Liu, Y.; Lemmon, M.A.; Radhakrishnan, R. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem. J.,  2012, 448(3), 417-423.
[http://dx.doi.org/10.1042/BJ20121513] [PMID:  23101586] 
[167] 
Spicer, J.F.; Rudman, S.M. EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Target. Oncol.,  2010, 5(4), 245-255.
[http://dx.doi.org/10.1007/s11523-010-0140-y] [PMID:  20574858] 
[168] 
Wei, H.; Duan, Y.; Gou, W.; Cui, J.; Ning, H.; Li, D.; Qin, Y.; Liu, Q.; Li, Y. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. Eur. J. Med. Chem.,  2019, 181, 111552.
[http://dx.doi.org/10.1016/j.ejmech.2019.07.055] [PMID:  31387063] 
[169] 
Zeng, Q.; Wang, J.; Cheng, Z.; Chen, K.; Johnström, P.; Varnäs, K.; Li, D.Y.; Yang, Z.F.; Zhang, X. Discovery and evaluation of clinical candidate azd3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor. J. Med. Chem.,  2015, 58(20), 8200-8215.
[http://dx.doi.org/10.1021/acs.jmedchem.5b01073] [PMID:  26313252] 
[170] 
Qin, X.; Lv, Y.; Liu, P.; Li, Z.; Hu, L.; Zeng, C.; Yang, L. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett.,  2016, 26(6), 1571-1575.
[http://dx.doi.org/10.1016/j.bmcl.2016.02.009] [PMID:  26879314] 
[171] 
Xia, G.; Chen, W.; Zhang, J.; Shao, J.; Zhang, Y.; Huang, W.; Zhang, L.; Qi, W.; Sun, X.; Li, B.; Xiang, Z.; Ma, C.; Xu, J.; Deng, H.; Li, Y.; Li, P.; Miao, H.; Han, J.; Liu, Y.; Shen, J.; Yu, Y. A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles. J. Med. Chem.,  2014, 57(23), 9889-9900.
[http://dx.doi.org/10.1021/jm5014659] [PMID:  25409491] 
[172] 
Qian, L.; Liu, Y.; Xu, Y.; Ji, W.; Wu, Q.; Liu, Y.; Gao, Q.; Su, C. Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways. Cancer Lett.,  2015, 368(1), 126-134.
[http://dx.doi.org/10.1016/j.canlet.2015.07.035] [PMID:  26259512] 
[173] 
Kim, H.; Lim, H.Y. Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways. J. Korean Med. Sci.,  2011, 26(12), 1563-1568.
[http://dx.doi.org/10.3346/jkms.2011.26.12.1563] [PMID:  22147992] 
[174] 
Liu, X.; Tian, S.; Liu, M.; Jian, L.; Zhao, L. Wogonin inhibits the proliferation and invasion, and induces the apoptosis of HepG2 and Bel7402 HCC cells through NF κB/Bcl-2, EGFR and EGFR downstream ERK/AKT signaling. Int. J. Mol. Med.,  2016, 38(4), 1250-1256.
[http://dx.doi.org/10.3892/ijmm.2016.2700] [PMID:  27499272] 
[175] 
Zhou, M.; Mok, M.T.; Sun, H.; Chan, A.W.; Huang, Y.; Cheng, A.S.; Xu, G. The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis. Oncogene,  2017, 36(29), 4135-4149.
[http://dx.doi.org/10.1038/onc.2017.38] [PMID:  28319060] 
[176] 
Jang, J-W.; Song, Y.; Kim, S-H.; Kim, J.S.; Kim, K.M.; Choi, E.K.; Kim, J.; Seo, H.R. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma. Cancer Lett.,  2017, 389, 1-10.
[http://dx.doi.org/10.1016/j.canlet.2016.12.023] [PMID:  28034805] 
[177] 
Zhou, Q.; Lui, V.W.; Yeo, W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol.,  2011, 7(10), 1149-1167.
[http://dx.doi.org/10.2217/fon.11.95] [PMID:  21992728] 
[178] 
Laplante, M.; Sabatini, D.M. mTOR signaling at a glance. J. Cell Sci.,  2009, 122(Pt 20), 3589-3594.
[http://dx.doi.org/10.1242/jcs.051011] [PMID:  19812304] 
[179] 
Xie, J.; Wang, X.; Proud, C.G. mTOR inhibitors in cancer therapy. F1000 Res.,  2016, 5, 2078.
[http://dx.doi.org/10.12688/f1000research.9207.1] [PMID:  27635236] 
[180] 
Villanueva, A.; Chiang, D.Y.; Newell, P.; Peix, J.; Thung, S.; Alsinet, C.; Tovar, V.; Roayaie, S.; Minguez, B.; Sole, M.; Battiston, C.; Van Laarhoven, S.; Fiel, M.I.; Di Feo, A.; Hoshida, Y.; Yea, S.; Toffanin, S.; Ramos, A.; Martignetti, J.A.; Mazzaferro, V.; Bruix, J.; Waxman, S.; Schwartz, M.; Meyerson, M.; Friedman, S.L.; Llovet, J.M. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology,  2008, 135(6), 1972-1983-1983.e1-11.
[http://dx.doi.org/10.1053/j.gastro.2008.08.008] [PMID:  18929564] 
[181] 
Ma, X.M.; Blenis, J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol.,  2009, 10(5), 307-318.
[http://dx.doi.org/10.1038/nrm2672] [PMID:  19339977] 
[182] 
Roohi, A.; Hojjat-Farsangi, M. Recent advances in targeting mTOR signaling pathway using small molecule inhibitors. J. Drug Target.,  2017, 25(3), 189-201.
[http://dx.doi.org/10.1080/1061186X.2016.1236112] [PMID:  27632356] 
[183] 
Chi, H. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol.,  2012, 12(5), 325-338.
[http://dx.doi.org/10.1038/nri3198] [PMID:  22517423] 
[184] 
Wang, Z.; Zhou, J.; Fan, J.; Tan, C-J.; Qiu, S-J.; Yu, Y.; Huang, X-W.; Tang, Z-Y. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol.,  2009, 135(5), 715-722.
[http://dx.doi.org/10.1007/s00432-008-0506-z] [PMID:  19002496] 
[185] 
Decaens, T.; Luciani, A.; Itti, E.; Hulin, A.; Roudot-Thoraval, F.; Laurent, A.; Zafrani, E.S.; Mallat, A.; Duvoux, C. Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma. Dig. Liver Dis.,  2012, 44(7), 610-616.
[http://dx.doi.org/10.1016/j.dld.2012.02.005] [PMID:  22459565] 
[186] 
Kelley, R.K.; Nimeiri, H.S.; Munster, P.N.; Vergo, M.T.; Huang, Y.; Li, C-M.; Hwang, J.; Mulcahy, M.F.; Yeh, B.M.; Kuhn, P.; Luttgen, M.S.; Grabowsky, J.A.; Stucky-Marshall, L.; Korn, W.M.; Ko, A.H.; Bergsland, E.K.; Benson, A.B. III.; Venook, A.P. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann. Oncol.,  2013, 24(7), 1900-1907.
[http://dx.doi.org/10.1093/annonc/mdt109] [PMID:  23519998] 
[187] 
Kelley, R.K.; Nimeiri, H.S.; Gordan, J.D.; Hwang, J.; McWhirter, R.M.; Kanakamedala, A.; Atreya, C.E.; Kulik, L.; Kircher, S.; Mulcahy, M.F.; Benson, A.B.; Venook, A.P. Phase II trial of temsirolimus (TEM) plus sorafenib (SOR) in hepatocellular carcinoma (HCC). J. Clin. Oncol,  2015, 33(Suppl_3), TPS501.
[http://dx.doi.org/10.1200/jco.2015.33.3_suppl.tps501] 
[188] 
Li, A.; Zhang, R.; Zhang, Y.; Liu, X.; Wang, R.; Liu, J.; Liu, X.; Xie, Y.; Cao, W.; Xu, R.; Ma, Y.; Cai, W.; Wu, B.; Cai, S.; Tang, X. BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway. Am. J. Transl. Res.,  2019, 11(9), 5573-5585.
[PMID:  31632530] 
[189] 
O’Reilly, K.E.; Rojo, F.; She, Q.B.; Solit, D.; Mills, G.B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D.J.; Ludwig, D.L.; Baselga, J.; Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res.,  2006, 66(3), 1500-1508.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-2925] [PMID:  16452206] 
[190] 
Kharas, M.G.; Janes, M.R.; Scarfone, V.M.; Lilly, M.B.; Knight, Z.A.; Shokat, K.M.; Fruman, D.A. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J. Clin. Invest.,  2008, 118(9), 3038-3050.
[http://dx.doi.org/10.1172/JCI33337] [PMID:  18704194] 
[191] 
Hugle, M.; Fulda, S. Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma. Cancer Lett.,  2015, 360(1), 1-9.
[http://dx.doi.org/10.1016/j.canlet.2014.12.016] [PMID:  25637161] 
[192] 
Lv, X.; Ma, X.; Hu, Y. Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment. Expert Opin. Drug Discov.,  2013, 8(8), 991-1012.
[http://dx.doi.org/10.1517/17460441.2013.800479] [PMID:  23668243] 
[193] 
Huang, Z.; Wu, Y.; Zhou, X.; Qian, J.; Zhu, W.; Shu, Y.; Liu, P. Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review. Future Oncol.,  2015, 11(11), 1687-1699.
[http://dx.doi.org/10.2217/fon.15.70] [PMID:  26043220] 
[194] 
Xiao, Z.; Lei, F.; Chen, X.; Wang, X.; Cao, L.; Ye, K.; Zhu, W.; Xu, S. Design, synthesis, and antitumor evaluation of quinoline-imidazole derivatives. Arch. Pharm. (Weinheim),  2018, 351(6), e1700407.
[http://dx.doi.org/10.1002/ardp.201700407] [PMID:  29732607] 
[195] 
Ma, X.; Lv, X.; Qiu, N.; Yang, B.; He, Q.; Hu, Y. Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): the design, synthesis and biological evaluation. Bioorg. Med. Chem.,  2015, 23(24), 7585-7596.
[http://dx.doi.org/10.1016/j.bmc.2015.11.003] [PMID:  26596710] 
[196] 
Ma, X.D.; Qiu, N.; Yang, B.; He, Q.J.; Hu, Y.Z. Novel quinoline-derived mTOR inhibitors with remarkable enzymatic and cellular activities: design, synthesis and biological evaluation. MedChemComm,  2016, 7(2), 297-310.
[http://dx.doi.org/10.1039/C5MD00401B] 
[197] 
Cheng, H.; Johnson, T.W.; Hoffman, J.E.; Guo, L.C.; Liu, Z.; Johnson, T.O.; Liu, K.K-C. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions. U.S. Patent 20110190326, 2009.
[198] 
Hu, M.; Huang, H.; Zhao, R.; Li, P.; Li, M.; Miao, H.; Chen, N.; Chen, M. AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma. Oncol. Rep.,  2014, 31(2), 649-656.
[http://dx.doi.org/10.3892/or.2013.2890] [PMID:  24297300] 
[199] 
Liu, M.; Gu, P.; Guo, W.; Fan, X. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor. Tumour Biol.,  2016, 37(8), 11039-11048.
[http://dx.doi.org/10.1007/s13277-015-4598-1] [PMID:  26897748] 
[200] 
Liao, H.; Huang, Y.; Guo, B.; Liang, B.; Liu, X.; Ou, H.; Jiang, C.; Li, X.; Yang, D. Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma. Am. J. Cancer Res.,  2014, 5(1), 125-139.
[PMID:  25628925] 
[201] 
Wang, K.; Fan, Y.; Chen, G.; Wang, Z.; Kong, D.; Zhang, P. MEK-ERK inhibition potentiates WAY-600-induced anti-cancer efficiency in preclinical hepatocellular carcinoma (HCC) models. Biochem. Biophys. Res. Commun.,  2016, 474(2), 330-337.
[http://dx.doi.org/10.1016/j.bbrc.2016.04.099] [PMID:  27107695] 
[202] 
Yongxi, T.; Haijun, H.; Jiaping, Z.; Guoliang, S.; Hongying, P. Autophagy inhibition sensitizes KU-0063794-mediated anti-HepG2 hepatocellular carcinoma cell activity in vitro and in vivo. Biochem. Biophys. Res. Commun.,  2015, 465(3), 494-500.
[http://dx.doi.org/10.1016/j.bbrc.2015.08.045] [PMID:  26278819] 
[203] 
Kang, H.G.; Wang, B.Z.; Zhang, J.; Liu, M.R.; Li, Y.X. Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol.,  2017, 41(2), 197-203.
[http://dx.doi.org/10.1016/j.clinre.2016.09.005] [PMID:  27863926] 
[204] 
Yang, S.; Liu, G. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol. Lett.,  2017, 13(3), 1041-1047.
[http://dx.doi.org/10.3892/ol.2017.5557] [PMID:  28454211] 
[205] 
Li, L.; Zhao, G.D.; Shi, Z.; Qi, L.L.; Zhou, L.Y.; Fu, Z.X. The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncol. Lett.,  2016, 12(5), 3045-3050.
[http://dx.doi.org/10.3892/ol.2016.5110] [PMID:  27899961] 
[206] 
Roberts, P.J.; Der, C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene,  2007, 26(22), 3291-3310.
[http://dx.doi.org/10.1038/sj.onc.1210422] [PMID:  17496923] 
[207] 
Kudo, M.; Ueshima, K.; Ikeda, M.; Torimura, T.; Tanabe, N.; Aikata, H.; Izumi, N.; Yamasaki, T.; Nojiri, S.; Hino, K.; Tsumura, H.; Kuzuya, T.; Isoda, N.; Yasui, K.; Yoshimura, K.; Okusaka, T.; Furuse, J.; Kokudo, N.; Okita, K.; Arai, Y. Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial. J. Clin. Oncol,  2018, 36(Suppl_4), 206.
[http://dx.doi.org/10.1200/JCO.2018.36.4_suppl.206] 
[208] 
Bruix, J.; Cheng, A.L.; Meinhardt, G.; Nakajima, K.; De Sanctis, Y.; Llovet, J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J. Hepatol.,  2017, 67(5), 999-1008.
[http://dx.doi.org/10.1016/j.jhep.2017.06.026] [PMID:  28687477] 
[209] 
Gong, X.; Qin, S. Study progression of anti-angiogenetic therapy and its combination with other agents for the treatment of advanced hepatocellular carcinoma. Hepatobiliary Surg. Nutr.,  2018, 7(6), 466-474.
[http://dx.doi.org/10.21037/hbsn.2018.11.04] [PMID:  30652091] 
[210] 
Li, X.; Qiu, M.; Wang, S.; Zhu, H.; Feng, B.; Zheng, L. A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours. Cancer Chemother. Pharmacol.,  2020, 85(3), 593-604.
[http://dx.doi.org/10.1007/s00280-020-04031-1] [PMID:  32008115] 
[211] 
Wan, P.T.C.; Garnett, M.J.; Roe, S.M.; Lee, S.; Niculescu-Duvaz, D.; Good, V.M.; Jones, C.M.; Marshall, C.J.; Springer, C.J.; Barford, D.; Marais, R.; Marais, R. Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell,  2004, 116(6), 855-867.
[http://dx.doi.org/10.1016/S0092-8674(04)00215-6] [PMID:  15035987] 
[212] 
Chu, J.H.; Zhao, C.R.; Song, Z.Y.; Wang, R.Q.; Qin, Y.Z.; Li, W.B.; Qu, X.J. 1082-39, an analogue of sorafenib, inhibited human cancer cell growth more potently than sorafenib. Biomed. Pharmacother.,  2014, 68(3), 335-341.
[http://dx.doi.org/10.1016/j.biopha.2014.01.010] [PMID:  24581722] 
[213] 
Yang, Z.; Fang, Z.; Wang, Z.X.; Wei, P. Synthesis and biological evaluation of sorafenib thiourea derivatives. Yao Xue Xue Bao,  2011, 46(9), 1093-1097.
[PMID:  22121780] 
[214] 
Yao, J.; He, Z.; Chen, J.; Sun, W.; Fang, H.; Xu, W. Design, synthesis and biological activities of sorafenib derivatives as antitumor agents. Bioorg. Med. Chem. Lett.,  2012, 22(21), 6549-6553.
[http://dx.doi.org/10.1016/j.bmcl.2012.09.031] [PMID:  23021967] 
[215] 
Wang, M.; Xu, S.; Wu, C.; Liu, X.; Tao, H.; Huang, Y.; Liu, Y.; Zheng, P.; Zhu, W. Design, synthesis and activity of novel sorafenib analogues bearing chalcone unit. Bioorg. Med. Chem. Lett.,  2016, 26(22), 5450-5454.
[http://dx.doi.org/10.1016/j.bmcl.2016.10.029] [PMID:  27777009] 
[216] 
Hwang, S.H.; Wecksler, A.T.; Zhang, G.; Morisseau, C.; Nguyen, L.V.; Fu, S.H.; Hammock, B.D. Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. Bioorg. Med. Chem. Lett.,  2013, 23(13), 3732-3737.
[http://dx.doi.org/10.1016/j.bmcl.2013.05.011] [PMID:  23726028] 
[217] 
Chen, F.; Fang, Y.; Zhao, R.; Le, J.; Zhang, B.; Huang, R.; Chen, Z.; Shao, J. Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma. Eur. J. Med. Chem.,  2019, 179, 916-935.
[http://dx.doi.org/10.1016/j.ejmech.2019.06.070] [PMID:  31306818] 
[218] 
Jiao, Y.; Xin, B.T.; Zhang, Y.; Wu, J.; Lu, X.; Zheng, Y.; Tang, W.; Zhou, X. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents. Eur. J. Med. Chem.,  2015, 90, 170-183.
[http://dx.doi.org/10.1016/j.ejmech.2014.11.008] [PMID:  25461318] 
[219] 
Facciorusso, A.; Licinio, R.; Carr, B.I.; Di Leo, A.; Barone, M. MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma. Expert Rev. Gastroenterol. Hepatol.,  2015, 9(7), 993-1003.
[http://dx.doi.org/10.1586/17474124.2015.1040763] [PMID:  25915713] 
[220] 
Tolcher, A.W.; Bendell, J.C.; Papadopoulos, K.P.; Burris, H.A., III; Patnaik, A.; Jones, S.F.; Rasco, D.; Cox, D.S.; Durante, M.; Bellew, K.M.; Park, J.; Le, N.T.; Infante, J.R. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Ann. Oncol.,  2015, 26(1), 58-64.
[http://dx.doi.org/10.1093/annonc/mdu482] [PMID:  25344362] 
[221] 
Huynh, H.; Ngo, V.C.; Koong, H.N.; Poon, D.; Choo, S.P.; Toh, H.C.; Thng, C.H.; Chow, P.; Ong, H.S.; Chung, A.; Goh, B.C.; Smith, P.D.; Soo, K.C. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J. Hepatol.,  2010, 52(1), 79-87.
[http://dx.doi.org/10.1016/j.jhep.2009.10.008] [PMID:  19910069] 
[222] 
Tai, W.M.; Yong, W.P.; Lim, C.; Low, L.S.; Tham, C.K.; Koh, T.S.; Ng, Q.S.; Wang, W.W.; Wang, L.Z.; Hartano, S.; Thng, C.H.; Huynh, H.; Lim, K.T.; Toh, H.C.; Goh, B.C.; Choo, S.P. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). Ann. Oncol.,  2016, 27(12), 2210-2215.
[http://dx.doi.org/10.1093/annonc/mdw415] [PMID:  27681866] 
[223] 
Lito, P.; Saborowski, A.; Yue, J.; Solomon, M.; Joseph, E.; Gadal, S.; Saborowski, M.; Kastenhuber, E.; Fellmann, C.; Ohara, K.; Morikami, K.; Miura, T.; Lukacs, C.; Ishii, N.; Lowe, S.; Rosen, N. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell,  2014, 25(5), 697-710.
[http://dx.doi.org/10.1016/j.ccr.2014.03.011] [PMID:  24746704] 
[224] 
Charette, N.; De Saeger, C.; Lannoy, V.; Horsmans, Y.; Leclercq, I.; Stärkel, P. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol. Cancer,  2010, 9(1), 256.
[http://dx.doi.org/10.1186/1476-4598-9-256] [PMID:  20860815] 
[225] 
Charette, N.; De Saeger, C.; Horsmans, Y.; Leclercq, I.; Stärkel, P. Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms. Cell Death Dis.,  2013, 4(1), e471.
[http://dx.doi.org/10.1038/cddis.2012.200] [PMID:  23348585] 
[226] 
Hennig, M.; Yip-Schneider, M.T.; Wentz, S.; Wu, H.; Hekmatyar, S.K.; Klein, P.; Bansal, N.; Schmidt, C.M. Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems. Hepatology,  2010, 51(4), 1218-1225.
[http://dx.doi.org/10.1002/hep.23470] [PMID:  20112426] 
[227] 
Wang, Y.; Nie, H.; Zhao, X.; Qin, Y.; Gong, X. Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways. BMC Cancer,  2016, 16(1), 742.
[http://dx.doi.org/10.1186/s12885-016-2767-2] [PMID:  27654866] 
[228] 
Yang, F.; Li, J.; Zhu, J.; Wang, D.; Chen, S.; Bai, X. Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-κB signaling pathway in H22 tumor-bearing mice. Eur. J. Pharmacol.,  2015, 754, 105-114.
[http://dx.doi.org/10.1016/j.ejphar.2015.02.015] [PMID:  25720342] 
[229] 
Burdeos, G.C.; Ito, J.; Eitsuka, T.; Nakagawa, K.; Kimura, F.; Miyazawa, T. δ and γ tocotrienols suppress human hepatocellular carcinoma cell proliferation via regulation of Ras-Raf-MEK-ERK pathway-associated upstream signaling. Food Funct.,  2016, 7(10), 4170-4174.
[http://dx.doi.org/10.1039/C6FO00826G] [PMID:  27713963] 
[230] 
Heindryckx, F.; Gerwins, P. Targeting the tumor stroma in hepatocellular carcinoma. World J. Hepatol.,  2015, 7(2), 165-176.
[http://dx.doi.org/10.4254/wjh.v7.i2.165] [PMID:  25729472] 
[231] 
Harding, J.J.; El Dika, I.; Abou-Alfa, G.K. Immunotherapy in hepatocellular carcinoma: primed to make a difference? Cancer,  2016, 122(3), 367-377.
[http://dx.doi.org/10.1002/cncr.29769] [PMID:  26540029] 
[232] 
Prieto, J.; Melero, I.; Sangro, B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol.,  2015, 12(12), 681-700.
[http://dx.doi.org/10.1038/nrgastro.2015.173] [PMID:  26484443] 
[233] 
Parry, R.V.; Chemnitz, J.M.; Frauwirth, K.A.; Lanfranco, A.R.; Braunstein, I.; Kobayashi, S.V.; Linsley, P.S.; Thompson, C.B.; Riley, J.L. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol.,  2005, 25(21), 9543-9553.
[http://dx.doi.org/10.1128/MCB.25.21.9543-9553.2005] [PMID:  16227604] 
[234] 
Lo, B.; Fritz, J.M.; Su, H.C.; Uzel, G.; Jordan, M.B.; Lenardo, M.J. CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. Blood,  2016, 128(8), 1037-1042.
[http://dx.doi.org/10.1182/blood-2016-04-712612] [PMID:  27418640] 
[235] 
Finkelmeier, F.; Waidmann, O.; Trojan, J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev. Anticancer Ther.,  2018, 18(12), 1169-1175.
[http://dx.doi.org/10.1080/14737140.2018.1535315] [PMID:  30304963] 
[236] 
Sangro, B.; Park, J.-W.; Cruz, C.M.D.; Anderson, J.; Lang, L.; Neely, J.; Shaw, J.W.; Cheng, A.-L. A randomized, multicenter, phase 3 study of nivolumab vs. sorafenib as firstline treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459. J. Clin. Oncol.,  2016, 34, TPS4147.
[http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.TPS4147] 
[237] 
Shrestha, R.; Bridle, K.R.; Crawford, D.H.G.; Jayachandran, A. Immune checkpoint blockade therapies for HCC: current status and future implications. Hepatoma Res.,  2019, 5, 32.
[http://dx.doi.org/10.20517/2394-5079.2019.24] 
[238] 
Exposito, M.J.J.; Akce, M.; Alvarez, J.L.M.; Assenat, E.; Balart, L.A.; Baron, A.D.; Decaens, T.; Heurgue-Berlot, A.; Martin, A.O.; Paik, S.W.; Poulart, V.; Sehbai, A.S.; Shemada, M.; Takemura, N.; Yoon, J.-H. CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs. placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation. Ann. Oncol.,  2018, 29(Suppl_8), viii267-viii268.
[http://dx.doi.org/10.1093/annonc/mdy282.166] 
[239] 
Zhu, A.X.; Finn, R.S.; Edeline, J.; Cattan, S.; Ogasawara, S.; Palmer, D.H.; Verslype, C.; Zagonel, V.; Fartoux, L.; Vogel, A.; Sarker, D.; Verset, G.; Chan, S.L.; Knox, J.J.; Daniele, B.; Ebbinghaus, S.; Ma, J.; Siegel, A.B.; Cheng, A.-L.; Kudo, M. Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update. J. Clin. Oncol.,  2018, 36(Suppl_15), 4020.
[http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.4020] 
[240] 
Finn, R.S.; Ryoo, B.-Y.; Merle, P.; Kudo, M.; Bouattour, M.; Lim, H.-Y.; Breder, V.V.; Edeline, J.; Chao, Y.; Ogasawara, S.; Yau, T.; Garrido, M.; Chan, S.L.; Knox, J.J.; Daniele, B.; Ebbinghaus, S.; Chen, E.; Siegel, A.B.; Zhu, A.X.; Cheng, A.-L. Results of KEYNOTE-240: phase 3 study of pembrolizumab (pembro) vs. best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J. Clin. Oncol.,  2019, 37(Suppl_15), 4004.
[http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.4004] 
[241] 
Pinato, D.J.; Cole, T.; Bengsch, B.; Tait, P.; Sayed, A.A.; Abomeli, F.; Gramenitskaya, D.; Allara, E.; Thomas, R.; Ward, C.; Wong, C.N.; Akarca, A.U.; Blanco, J.M.; Marafioti, T.; Marchesi, J.; Sharma, R. 750PA phase Ib study of Pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL Ann. Oncol.,  2019, 30(Suppl_5), v288.
[http://dx.doi.org/10.1093/annonc/mdz247.076] 
[242] 
Qin, S.; Finn, R.S.; Kudo, M.; Meyer, T.; Vogel, A.; Ducreux, M.; Mercade, T.M.; Tomasello, G.; Boisserie, F.; Hou, J.; Li, C.; Song, J.; Zhu, A.X.  A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of Tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepato3146 Current Medicinal Chemistry, 2021, Vol. 28, No. 16 Wang et al. cellular carcinoma J. Clin. Oncol,  2018, 36(15_Suppl), TPS3110.
[http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.TPS3110] 
[243] 
Huang, J.; Mo, H.; Wu, D.; Chen, X.; Ma, L.; Lan, B.; Qu, D.; Yang, Q.; Xu, B. Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors J. Clin.Oncol.,  2017, 35(15_Suppl), e15572.
[http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.e15572] 
[244] 
Qin, S.; Chen, Z.; Liu, Y.; Xiong, J.; Ren, Z.; Meng, Z.; Gu, S.; Wang, L.; Zou, J. A phase II study of anti-PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer J. Clin.Oncol.,  2019, 35(15_Suppl), 4074.
[http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.4074] 
[245] 
Busato, D.; Mossenta, M.; Baboci, L.; Di Cintio, F.; Toffoli, G.; Dal Bo, M. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Rev. Clin. Pharmacol.,  2019, 12(5), 453-470.
[http://dx.doi.org/10.1080/17512433.2019.1598859] [PMID:  30907177] 
[246] 
Nishida, N.; Kudo, M. Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. Hepatol. Res.,  2018, 48(8), 622-634.
[http://dx.doi.org/10.1111/hepr.13191] [PMID:  29734514] 
[247] 
Duffy, A.G.; Makarova-Rusher, O.V.; Pratt, D.; Kleiner, D.E.; Fioravanti, S.; Walker, M.; Carey, S.; Figg, W.D.; Steinberg, S.M.; Anderson, V.; Levy, E.; Krishnasamy, V.; Wood, B.J.; Greten, T.F. Tremelimumab, a monoclonal antibody against CTLA-4, in combination with subtotal ablation (trans-catheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or cryoablation) in patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC). J. Clin.Oncol.,  2016, 34(4_Suppl), 270.
[http://dx.doi.org/10.1200/jco.2016.34.4_suppl.270] 
[248] 
Abou-Alfa, G.K.; Chan, S.L.; Furuse, J.; Galle, P.R.; Kelley, R.K.; Qin, S.; Armstrong, J.; Darilay, A.; Vlahovic, G.; Negro, A.; Sangro, B. A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. J. Clin.Oncol.,  2018, 36(15_Suppl), TPS4144.
[http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.TPS4144] 
[249] 
Kelley, R.K.; Abou-Alfa, G.K.; Bendell, J.C.; Kim, T-Y.; Borad, M.J.; Yong, W-P.; Morse, M.; Kang, Y-K.; Rebelatto, M.; Makowsky, M.; Xiao, F.; Morris, S.R.; Sangro, B. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. J. Clin.Oncol.,  2017, 35(15_Suppl), 4073.
[http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.4073] 
[250] 
Floudas, C.S.; Xie, C.; Brar, G.; Morelli, M.P.; Fioravanti, S.; Walker, M.; Mabry-Hrones, D.; Wood, B.J.; Levy, E.B.; Krishnasamy, V.P.; Greten, T.F. Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC). J. Clin.Oncol.,  2019, 37(4_Suppl), 336.
[http://dx.doi.org/10.1200/JCO.2019.37.4_suppl.336] 
[251] 
Dawkins, J.; Webster, R.M. The hepatocellular carcinoma market. Nat. Rev. Drug Discov.,  2019, 18(1), 13-14.
[http://dx.doi.org/10.1038/nrd.2018.146] [PMID:  30168534] 
[252] 
Lee, M.; Ryoo, B.Y.; Hsu, C.H.; Numata, K.; Stein, S.; Verret, W.; Hack, S.; Spahn, J.; Liu, B.; Abdullah, H.; He, R.; Lee, K.H. LBA39 - Randomised efficacy and safety results for atezolizumab (atezo) + bevacizumab (bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). JAnn. Oncol.,  2019, 30(Suppl.5), v875.
[http://dx.doi.org/10.1093/annonc/mdz394.030] 
[253] 
Harding, J.J. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials. Future Oncol.,  2018, 14(22), 2293-2302.
[http://dx.doi.org/10.2217/fon-2018-0008] [PMID:  29663837] 
[254] 
Singh, A.V.; Sitti, M. Targeted drug delivery and imaging using mobile milli/microrobots: a promising future towards theranostic pharmaceutical design. Curr. Pharm. Des.,  2016, 22(11), 1418-1428.
[http://dx.doi.org/10.2174/1381612822666151210124326] [PMID:  26654436] 
[255] 
Singh, A.V.; Ansari, M.H.D.; Laux, P.; Luch, A. Micro-nanorobots: important considerations when developing novel drug delivery platforms. Expert Opin. Drug Deliv.,  2019, 16(11), 1259-1275.
[http://dx.doi.org/10.1080/17425247.2019.1676228] [PMID:  31580731] 
[256] 
Sun, M.; Fan, X.; Meng, X.; Song, J.; Chen, W.; Sun, L.; Xie, H. Magnetic biohybrid micromotors with high maneuverability for efficient drug loading and targeted drug delivery. Nanoscale,  2019, 11(39), 18382-18392.
[http://dx.doi.org/10.1039/c9nr06221a] [PMID:  31573587] 
[257] 
Singh, A.V.; Ansari, M.H.D.; Dayan, C.B.; Giltinan, J.; Wang, S.; Yu, Y.; Kishore, V.; Laux, P.; Luch, A.; Sitti, M. Multifunctional magnetic hairbot for untethered osteogenesis, ultrasound contrast imaging and drug delivery. Biomaterials,  2019, 219, 119394.
[http://dx.doi.org/10.1016/j.biomaterials.2019.119394] [PMID:  31382208] 
[258] 
Baxi, S.; Yang, A.; Gennarelli, R.L.; Khan, N.; Wang, Z.; Boyce, L.; Korenstein, D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ,  2018, 360, k793.
[http://dx.doi.org/10.1136/bmj.k793] [PMID:  29540345] 
Rights & Permissions Print Cite
Article Metrics
66
1
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0929867327666201013162144	Print ISSN 0929-8673
Publisher Name Bentham Science Publisher	Online ISSN 1875-533X
当代药物化学

肝细胞癌靶向治疗和免疫治疗的研究进展

摘要

当代药物化学

肝细胞癌靶向治疗和免疫治疗的研究进展

摘要 Play Pause

Related Journals

Related Books

Related Articles

摘要
